Psychoanalyst attitudes towards psychedelic-assisted therapy
Eli Kraiem, Marc J. Diener, Jeffrey Guss, Linnea Mavrides, Sally Saban
Drugs Education Prevention and Policy June 4, 2024 DOI: 10.1080/09687637.2024.2359444 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Quantitative study Peer reviewed |
|---|---|
| Sample size | 130 |
| Population | Graduate-level trained psychoanalysts in at least part-time clinical practice |
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychoanalysis Psychotherapist |
| Citations | 4 |
| Key points | Psychoanalysts were cautiously supportive of PAT and optimistic about its potential but believed it ineffective for substance use disorders, and prior personal psychedelic use was associated with more positive attitudes. |
Abstract
Background Numerous clinical trials have supported psychedelic-assisted therapy (PAT) as a treatment for psychiatric disorders such as depression, anxiety, post-traumatic stress, and substance use. While empirical evidence indicates PAT’s benefits, the perspectives of mental health practitioners on this topic remain unclear.Methods This quantitative study attempted to capture psychoanalyst practitioners’ attitudes toward PAT. A sample of 130 graduate-level trained psychoanalysts in at least part-time clinical practice was recruited to participate in an online survey.Results The study found that psychoanalysts were cautiously supportive of PAT, open to their clients engaging in PAT, and optimistic about PAT’s potential in treating mental disorders. Additionally, they reported that PAT would be ineffective in treating substance use disorders (SUDs). Lastly, participants who reported a history of psychedelic use were significantly more likely to have greater positive attitudes toward PAT than those who had not.Conclusion Results indicate the potential for misinformation about psychedelics and a lingering cultural stigma regarding the utility of psychedelics in the therapeutic environment among psychoanalysts. Therefore, education on the risks, potential benefits, and limitations of the evidence base of psychedelics and their effectiveness across psychiatric disorders appears warranted in the psychoanalytic community.
Citations in the library
Cited by 4
- Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach. Frontiers in Psychiatry 2025
- My Bad, You Got This: witnessing, therapist attitude and the synergy between psychedelics and inner healing intelligence in the treatment of trauma. Frontiers in Psychology 2025
- Attitudes and Perceptions of Portuguese Psychiatrists and Psychologists on the Clinical Use of Ketamine. Acta Médica Portuguesa May 2, 2025
- Attitudes of Mental Healthcare Professionals Towards the Use of Psychedelics in the Treatment of Substance Use Disorders: A Systematic Review Journal of Psychoactive Drugs June 17, 2026
Cites 43
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
and 38 more in the library